Year: 2026

Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s control Platform-as-a-service model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all sizes — addressing a market where the top 20 pharma companies invested approximately $167 billion in R&D in 2024 but have only recently begun to deploy meaningful AI budgets KALA to serve as its own first deployment client, applying Researgency to its proprietary MSC-S biological datasets and KPI-012 clinical program before scaling to external biotech partners Exclusive worldwide license secured for the Researgency platform in the biotechnology field...

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD), a global leader in autonomous driving technology, today announced that it will release its unaudited financial results for the fourth quarter and full year 2025 on Monday, March 23, 2026, before the open of the U.S. markets. The Company’s management will host an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 23, 2026 or 8:00 P.M. Hong Kong Time on the same day to discuss the results. Details for the conference call are as follows: Event Title: WeRide Inc. Fourth Quarter and Full Year 2025 Earnings Call English Registration Link: https://register-conf.media-server.com/register/BI98ad9a5da2d8418781930021448b277b Chinese Simultaneous Interpretation Registration Link (listen-only mode): https://register-conf.media-server.com/register/BI5cdaf73794244bef8f4e6c8a09f2a403 All...

HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today it has been awarded a 10-year catalyst supply contract by Indorama Eleme Fertilizer & Chemicals FZE for its entire ammonia plant portfolio. This marks the first long‑term catalyst agreement for KBR in the ammonia sector, further reinforcing the company’s position as a leading ammonia solutions provider globally. Under the terms of the contract, KBR will provide complete catalyst solutions for Indorama’s six ammonia plants in Nigeria, Georgia, Uzbekistan and India. “We are proud to build on our long and successful relationship with Indorama, which spans multiple ammonia projects and decades of collaboration, and this new project extends our support beyond technology licensing into long‑term catalyst solutions,” said Jay Ibrahim, President, KBR Sustainable...

Fiscal Year 2025 versus 2024 1,047 total centers in 44 states, a 1.9% decrease versus 1,067 centers in the prior year period. System-wide sales of $947.3 million decreased 0.4% Total revenue of $206.6 million decreased 4.7% Same-store sales increased 0.2% GAAP net income of $11.9 million decreased 19.2% Adjusted Net Income of $36.2 million decreased 11.6% Adjusted EBITDA of $73.3 million decreased 3.0%PLANO, Texas, March 04, 2026 (GLOBE NEWSWIRE) — Today, European Wax Center, Inc. (NASDAQ: EWCZ), the leading franchisor and operator of out-of-home waxing services in the United States, reports financial results for the 13 and 52 weeks ended January 3, 2026. Results for the Fourth Quarter of Fiscal 2025 versus Fiscal 2024Franchisees opened 1 and closed 7 centers. We ended the quarter with 1,047 centers, representing a 1.9%...

Hod Hasharon, Israel, March 04, 2026 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative Security-as-a-Service (SECaaS) and network intelligence solutions for communications service providers and enterprises, today announced that management will be meeting with investors at the Cantor Fitzgerald Global Technology Conference in New York City on March 11, 2026. Allot’s CEO, Eyal Harari will be meeting with institutional investors in a one-on-one setting at the conference. To schedule a meeting with Allot’s management at the conference, please be in contact with your Cantor Fitzgerald Representative or with Allot’s investor relations team.   About Allot Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a leading provider of innovative converged cybersecurity solutions and network intelligence...

Stockholm, 4th of March 2026 – Virtune AB (Publ) (“Virtune”) today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm, Nasdaq Helsinki and Xetra (ISIN code SE0023260716). In addition to the Virtune Crypto Altcoin Index ETP, Virtune’s product portfolio includes: Virtune Bitcoin ETPVirtune Staked Ethereum ETPVirtune Stellar ETPVirtune Staked Solana ETPVirtune Staked Polkadot ETPVirtune XRP ETPVirtune Avalanche ETPVirtune Litecoin ETPVirtune Chainlink ETPVirtune Arbitrum ETPVirtune Polygon ETPVirtune Staked Cardano ETPVirtune Crypto Top 10 Index ETP SEKVirtune Crypto Top 10 Index ETP EURVirtune Bitcoin Prime ETPVirtune Coinbase 50 Index ETPVirtune Staked Near ETP Virtune Sui ETPVirtune Stablecoin Index ETPVirtune Bittensor ETPVirtune BNB ETP Index allocation...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy®—the first and only approved needle-free adrenaline-based product—over traditional adrenaline auto-injectors.i,ii The late-breaking data, presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, United States, suggest EURneffy® has the potential to address persistent practical and psychological barriers that limit consistent auto-injector availability and usage, leaving many patients without life-saving medication when they need it most. Research shows that approximately half of those living with a severe allergy did not administer their auto-injector when needed in an emergencyiii...

Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for daridorexant, a dual orexin receptor antagonist, for the treatment of adult patients with insomnia. This submission follows positive data from the Phase 3 trial of daridorexant in South...